Gold Member Since 2016
Nanjing Bangnuo Biotechnology Co., Ltd.

Evista, Bone, Uterus manufacturer / supplier in China, offering Anti Estrogen CAS 82640-04-8 Raloxifene Hydrochloride for Breast Cancer Osteoporosis, USP32 Local Anesthetics CAS 94-24-6 Tetracaine as Antipruritic, Pain and Fever Reduction Pharmaceutical Intermedaite CAS 103-90-2 Paracetamol and so on.

(/ )

Supplier Homepage Product Anti Estrogen Drugs Anti Estrogen CAS 82640-04-8 Raloxifene Hydrochloride for Breast Cancer Osteoporosis

Anti Estrogen CAS 82640-04-8 Raloxifene Hydrochloride for Breast Cancer Osteoporosis

FOB Price: US $1.5-12 / gram
Min. Order: 10 gram
Min. Order FOB Price
10 gram US $1.5-12/ gram
Get Latest Price
Production Capacity: 800 Kg/Month
Transport Package: 10g, 20g, 50g, 100g Per Aluminum Foil Bag
Payment Terms: T/T, Western Union, Money Gram, Bitcoin

Request a custom order and have something just for you!

Send Customized Request
Basic Info
  • Model NO.: 82640-04-8
  • Customized: Non-Customized
  • Suitable for: Elderly, Adult
  • Purity: >99%
  • Origin: Made in China
  • Powder: Yes
  • Certification: ISO 9001, SGS, Kosher
  • State: Solid
  • Trademark: NJBN STEROID
Product Description
99% Anti Estrogen for Prevention of Breast Cancer and Osteoporosis Raloxifene Hydrochloride CAS 82640-04-8
 
1. Quick Detail:
 
Product NameRaloxifene hydrochloride
AliasRaloxifene HCL; KEOXIFENE
CAS82640-04-8
Assay99.0%
Appearancelight yellow powder
Molecular FormulaC28H28ClNO4S
Molecular Weight510.04
GradePharmaceutical Grade
StorageShading, Confined Preservation
Brand NameNJBN STEROID
 
Description :
 
Evista (Raloxifene hydrochloride) is an estrogen agonist / antagonist, referred to as a Selective estrogen receptor modulator (SERMs) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely settlement through binding to estrogen receptors. This binding results in the activation of Pathways to estrogenic in some tissues (agonist) and and the Blockade of estrogenic Foundation in other tissues (antagonist).

Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial of the records about the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals.
Application :
( use in cancer )
 
 
Raloxifene hydrochloride is approved to prevent:
Breast cancer. It is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis.

Raloxifene hydrochloride is also approved to prevent and treat:
Osteoporosis in postmenopausal women.
Raloxifene hydrochloride is also being studied in the treatment of other types of cancer.
 

Application :

Evista (Raloxifene hydrochloride) is an estrogen agonist / antagonist, referred to as a Selective estrogen receptor modulator (SERMs) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely settlement through binding to estrogen receptors. This binding results in the activation of Pathways to estrogenic in some tissues (agonists) and and the Blockade of estrogenic Foundation in other tissues (the antagonist). The agonistic or antagonistic activity of raloxiffene depends on the extent of the recruitment of coactivators and corepressors to the estrogen receptor (ER), the promoter of the target gene. Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorptive and bone Turnovo, increases bone mineral density and decreases fracture incidence.

4. COA :
 
ITEMSSPECIFICATIONRESULT
Characters  
AppearanceWhite &off-white powderConform
 
Solubility
Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water 
Conform
IdentificationsInfrared AbsorptionConform
 ChlorideConform
Tests
 
Loss on drying≤0.5%0.4%
 Residue on ignition≤0.1%0.06%
 Heavy metals≤10ppmConform
 
RRelated substances
 
Raloxifene Impurity1≤0.20 %0.10%
 Any unspecified individual impurity 2
 
≤0.10%Max. 0.08%
 Total impurities≤0.50%0.40%
AssayRaloxifene HCl≥98.0%99.0%
 
5. Competitive Advantages:
 
As a pharmaceutical manufacturer, Nanjing Bangnuo Biotechnology Co., Ltd. specializes in steroid raw material and pharmaceutical raw materials. Over the years, we have been committed to provide the top cost-effective products and services to our customers.
 
Our products have been approved by many organizations and institutions, such as ISO9001 and SGS, etc. And our products have been exported to all over the world. The products can be served in gym fields, athletes fields and medical institutions, etc. 
 
Discreet package will be adopted to ensure the delivery safety.
 
Shipping: Within 24 hours after receiving the payment by express delivery (DHL, TNT, FedEx, HKEMS, UPS, EMS, etc.)
 
Payment Terms: T/T, West Union, Money Gram and Bitcoin.
 
Please feel free to inquire us for more details.
You Might Also Like
Send your message to this supplier
Avatar
Mr. Gary
*From:
To: Mr. Gary
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category